


JELMYTO product information specification sheet



Storage¹

Store the JELMYTO carton at 20°C to 25°C (68°F to 77°F); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Avoid excessive heat over 40°C (104°F).

JELMYTO is a cytotoxic drug. Follow applicable special handling and disposal procedures.

Dispensing pack	1 carton
NDC ¹	72493-103-03 or 72493-0103-03
Description ¹	Two 40 mg (each) single-dose vials of mitomycin for pyelocalyceal solution One 20 mL single-dose vial of sterile hydrogel to be used for reconstitution
HCPCS Level II code ^{2*}	J9281
WAC [†]	\$23,227 per carton



* Content is informational only and does not constitute medical, legal, or reimbursement advice and represents no statement, promise, or guarantee of payment.

[†] WAC is subject to change at the election of UroGen.

HCPCS=Healthcare Common Procedure Coding System; NDC=National Drug Code; WAC=wholesale acquisition cost.

JELMYTO is supplied in a single-dose carton containing 2 vials of sterile lyophilized mitomycin for pyelocalyceal solution, 40 mg each, and 1 vial of 20 mL of sterile hydrogel, to be used as a vehicle for reconstitution.¹

Mitomycin for pyelocalyceal solution is a sterile, lyophilized, grey to greyish-purple cake or powder that contains mitomycin 40 mg and mannitol 80 mg in each vial.¹

Sterile hydrogel is a sterile, clear, colorless gel with or without bubbles at room temperature or clear, colorless liquid at 2°C to 8°C (36°F to 46°F), which contains 0.04 g hydroxypropyl methylcellulose, 5.67 g poloxamer, 0.21 g polyethylene glycol, and water for injection in each vial.¹

Once reconstituted, JELMYTO is a clear, purple, viscous liquid at 2°C to 8°C (36°F to 46°F) or semisolid gel at room temperature with a concentration of 4 mg/mL of mitomycin, which may contain a few visible particles and have a pH between 6.0 and 8.0.¹

Please click [here](#) for Full Prescribing Information, Instructions for Pharmacy and Instructions for Administration for JELMYTO.



UROGEN SUPPORT IS AVAILABLE TO ASSIST YOU AND YOUR ELIGIBLE PATIENTS



Visit www.JELMYTO.com/hcp/support to learn more about:

- Comprehensive access and reimbursement support services
- Patient affordability and financial assistance for eligible patients. Additional restrictions and limitations may apply
- Product acquisition and preparation coordination

 [855-JELMYTO \(855-535-6986\)](tel:855-535-6986)

 [833-664-7216](tel:833-664-7216)

 www.JELMYTO.com/hcp/support

Please click [here](#) for Full Prescribing Information, Instructions for Pharmacy and Instructions for Administration for JELMYTO.

References: **1.** JELMYTO [package insert]. Princeton, NJ: UroGen Pharma, Inc.; 2022. **2.** Centers for Medicare & Medicaid Services. CMS Healthcare Common Procedure Coding System (HCPCS) application summaries and coding decisions: third quarter, 2020 coding cycle for drug and biological products. Accessed June 3, 2022. <https://www.cms.gov/files/document/2020-hcpcs-application-summary-quarter-3-2020-drugs-and-biologics.pdf>

JELMYTO is a registered trademark and UroGen Support is a trademark of UroGen Pharma, Ltd.
©2023 UroGen Pharma, Inc. All rights reserved.
US-JEL-00226 06/23

